CAR T-Cell Immunotherapy Market Size, Share, Trends & Analysis By Type, Regional Outlook, Industry Insights, Key Players and Applications Report 2021-2027

Report Summary

CAR T-Cell Immunotherapy is a new type of cancer treatment. This emerging treatment represents one of the biggest breakthroughs since the introduction of chemotherapy. T cells is a type of white blood cell extracted from the patient’s blood by doctors, and added an artificial receptor to their surface. When infused into a patient, the cells get multiplied and stay in the body as “living drugs” and help in detecting and fighting cancer. CAR-T cell therapy is defined as a type of immunotherapy that teaches T cells to recognize and destroy cancer.
In 2020, the global CAR T-Cell Immunotherapy market size was xx million US$ and it is expected to reach xx million US$ by the end of 2027, with a CAGR of xx% during 2021-2027.

This report focuses on the global CAR T-Cell Immunotherapy status, future forecast, growth opportunity, key market and key players. The study objectives are to present the CAR T-Cell Immunotherapy development in United States, Europe and China.

The key players covered in this study
AbbVie
Celgene
Kite Pharma
Oxford BioMedica
Novartis
Gilead
Pfizer
Cellectis
Bellicum
Mustang Bio
CARsgen Therapeutics
Xyphos
Minerva Biotechnologies
Adaptimmune
Ziopharm Oncology
Aurora Biopharma
Creative Biolabs

Market segment by Type, the product can be split into
Monotherapy
Combination Therapy

Market segment by Application, split into
Hematologic Malignancies
Solid Malignancies

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:
To analyze global CAR T-Cell Immunotherapy status, future forecast, growth opportunity, key market and key players.
To present the CAR T-Cell Immunotherapy development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of CAR T-Cell Immunotherapy are as follows:
History Year: 2017-2020
Base Year: 2020
Estimated Year: 2020
Forecast Year 2021 to 2027
For the data information by region, company, type and application, 2020 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Table Of Contents

Table of Contents

1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global CAR T-Cell Immunotherapy Market Size Growth Rate by Type (2017-2027)
1.4.2 Monotherapy
1.4.3 Combination Therapy
1.5 Market by Application
1.5.1 Global CAR T-Cell Immunotherapy Market Share by Application (2017-2027)
1.5.2 Hematologic Malignancies
1.5.3 Solid Malignancies
1.6 Study Objectives
1.7 Years Considered

2 Global Growth Trends
2.1 CAR T-Cell Immunotherapy Market Size
2.2 CAR T-Cell Immunotherapy Growth Trends by Regions
2.2.1 CAR T-Cell Immunotherapy Market Size by Regions (2017-2027)
2.2.2 CAR T-Cell Immunotherapy Market Share by Regions (2017-2020)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities

3 Market Share by Key Players
3.1 CAR T-Cell Immunotherapy Market Size by Manufacturers
3.1.1 Global CAR T-Cell Immunotherapy Revenue by Manufacturers (2017-2020)
3.1.2 Global CAR T-Cell Immunotherapy Revenue Market Share by Manufacturers (2017-2020)
3.1.3 Global CAR T-Cell Immunotherapy Market Concentration Ratio (CR5 and HHI)
3.2 CAR T-Cell Immunotherapy Key Players Head office and Area Served
3.3 Key Players CAR T-Cell Immunotherapy Product/Solution/Service
3.4 Date of Enter into CAR T-Cell Immunotherapy Market
3.5 Mergers & Acquisitions, Expansion Plans

4 Breakdown Data by Type and Application
4.1 Global CAR T-Cell Immunotherapy Market Size by Type (2017-2020)
4.2 Global CAR T-Cell Immunotherapy Market Size by Application (2017-2020)

5 United States
5.1 United States CAR T-Cell Immunotherapy Market Size (2017-2020)
5.2 CAR T-Cell Immunotherapy Key Players in United States
5.3 United States CAR T-Cell Immunotherapy Market Size by Type
5.4 United States CAR T-Cell Immunotherapy Market Size by Application

6 Europe
6.1 Europe CAR T-Cell Immunotherapy Market Size (2017-2020)
6.2 CAR T-Cell Immunotherapy Key Players in Europe
6.3 Europe CAR T-Cell Immunotherapy Market Size by Type
6.4 Europe CAR T-Cell Immunotherapy Market Size by Application

7 China
7.1 China CAR T-Cell Immunotherapy Market Size (2017-2020)
7.2 CAR T-Cell Immunotherapy Key Players in China
7.3 China CAR T-Cell Immunotherapy Market Size by Type
7.4 China CAR T-Cell Immunotherapy Market Size by Application

8 Japan
8.1 Japan CAR T-Cell Immunotherapy Market Size (2017-2020)
8.2 CAR T-Cell Immunotherapy Key Players in Japan
8.3 Japan CAR T-Cell Immunotherapy Market Size by Type
8.4 Japan CAR T-Cell Immunotherapy Market Size by Application

9 Southeast Asia
9.1 Southeast Asia CAR T-Cell Immunotherapy Market Size (2017-2020)
9.2 CAR T-Cell Immunotherapy Key Players in Southeast Asia
9.3 Southeast Asia CAR T-Cell Immunotherapy Market Size by Type
9.4 Southeast Asia CAR T-Cell Immunotherapy Market Size by Application

10 India
10.1 India CAR T-Cell Immunotherapy Market Size (2017-2020)
10.2 CAR T-Cell Immunotherapy Key Players in India
10.3 India CAR T-Cell Immunotherapy Market Size by Type
10.4 India CAR T-Cell Immunotherapy Market Size by Application

11 Central & South America
11.1 Central & South America CAR T-Cell Immunotherapy Market Size (2017-2020)
11.2 CAR T-Cell Immunotherapy Key Players in Central & South America
11.3 Central & South America CAR T-Cell Immunotherapy Market Size by Type
11.4 Central & South America CAR T-Cell Immunotherapy Market Size by Application

12 International Players Profiles
12.1 AbbVie
12.1.1 AbbVie Company Details
12.1.2 Company Description and Business Overview
12.1.3 CAR T-Cell Immunotherapy Introduction
12.1.4 AbbVie Revenue in CAR T-Cell Immunotherapy Business (2017-2020)
12.1.5 AbbVie Recent Development
12.2 Celgene
12.2.1 Celgene Company Details
12.2.2 Company Description and Business Overview
12.2.3 CAR T-Cell Immunotherapy Introduction
12.2.4 Celgene Revenue in CAR T-Cell Immunotherapy Business (2017-2020)
12.2.5 Celgene Recent Development
12.3 Kite Pharma
12.3.1 Kite Pharma Company Details
12.3.2 Company Description and Business Overview
12.3.3 CAR T-Cell Immunotherapy Introduction
12.3.4 Kite Pharma Revenue in CAR T-Cell Immunotherapy Business (2017-2020)
12.3.5 Kite Pharma Recent Development
12.4 Oxford BioMedica
12.4.1 Oxford BioMedica Company Details
12.4.2 Company Description and Business Overview
12.4.3 CAR T-Cell Immunotherapy Introduction
12.4.4 Oxford BioMedica Revenue in CAR T-Cell Immunotherapy Business (2017-2020)
12.4.5 Oxford BioMedica Recent Development
12.5 Novartis
12.5.1 Novartis Company Details
12.5.2 Company Description and Business Overview
12.5.3 CAR T-Cell Immunotherapy Introduction
12.5.4 Novartis Revenue in CAR T-Cell Immunotherapy Business (2017-2020)
12.5.5 Novartis Recent Development
12.6 Gilead
12.6.1 Gilead Company Details
12.6.2 Company Description and Business Overview
12.6.3 CAR T-Cell Immunotherapy Introduction
12.6.4 Gilead Revenue in CAR T-Cell Immunotherapy Business (2017-2020)
12.6.5 Gilead Recent Development
12.7 Pfizer
12.7.1 Pfizer Company Details
12.7.2 Company Description and Business Overview
12.7.3 CAR T-Cell Immunotherapy Introduction
12.7.4 Pfizer Revenue in CAR T-Cell Immunotherapy Business (2017-2020)
12.7.5 Pfizer Recent Development
12.8 Cellectis
12.8.1 Cellectis Company Details
12.8.2 Company Description and Business Overview
12.8.3 CAR T-Cell Immunotherapy Introduction
12.8.4 Cellectis Revenue in CAR T-Cell Immunotherapy Business (2017-2020)
12.8.5 Cellectis Recent Development
12.9 Bellicum
12.9.1 Bellicum Company Details
12.9.2 Company Description and Business Overview
12.9.3 CAR T-Cell Immunotherapy Introduction
12.9.4 Bellicum Revenue in CAR T-Cell Immunotherapy Business (2017-2020)
12.9.5 Bellicum Recent Development
12.10 Mustang Bio
12.10.1 Mustang Bio Company Details
12.10.2 Company Description and Business Overview
12.10.3 CAR T-Cell Immunotherapy Introduction
12.10.4 Mustang Bio Revenue in CAR T-Cell Immunotherapy Business (2017-2020)
12.10.5 Mustang Bio Recent Development
12.11 CARsgen Therapeutics
12.12 Xyphos
12.13 Minerva Biotechnologies
12.14 Adaptimmune
12.15 Ziopharm Oncology
12.16 Aurora Biopharma
12.17 Creative Biolabs

13 Market Forecast 2021-2027
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2021-2027)
13.10 Market Size Forecast by Application (2021-2027)

14 Analyst's Viewpoints/Conclusions

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details